vilaprisan
Small moleculeexperimental
Vilaprisan is a synthetic and steroidal selective progesterone receptor modulator (SPRM) which is under development by Bayer HealthCare Pharmaceuticals for the treatment of endometriosis and uterine fibroids. It is a potent and highly selective partial agonist of the progesterone receptor (PR). As of 2017, the drug is in phase II clinical trials for the aforementioned indications. — Wikipedia
Clinical trial activity
17 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
9
Phase 3
6
Phase 4
0
Earliest trial started Nov 1, 2011 (NCT01816815)
Timeline
Indications
Mechanism of action
- Progesterone receptorMODULATOR
PGR modulator
Chemistry & pharmacology
Loading structure…
SMILES
C[C@]12C[C@H](c3ccc(S(C)(=O)=O)cc3)C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C(F)(F)C(F)(F)F- Mol. weight
- 544.58 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaVilaprisan ↗
- ChEMBLCHEMBL3989936 ↗
Also known as
- bay1002670
- bay1002670
- vilaprisan
- vilaprisan
- vilaprisan
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03699176 | Phase 3 | Oct 27, 2018 | Bayer |
| NCT03573336 | Phase 2 | Jul 4, 2018 | Bayer |
| NCT03476928 | Phase 3 | Mar 30, 2018 | Bayer |
| NCT03411980 | Phase 1 | Feb 2, 2018 | Bayer |
| NCT03400956 | Phase 3 | Jan 24, 2018 | Bayer |
| NCT03400943 | Phase 3 | Jan 17, 2018 | Bayer |
| NCT03342859 | Phase 1 | Nov 16, 2017 | Bayer |
| NCT03240523 | Phase 3 | Jul 31, 2017 | Bayer |
| NCT03210246 | Phase 1 | Jul 17, 2017 | Bayer |
| NCT03194646 | Phase 3 | Jun 30, 2017 | Bayer |
| NCT03092999 | Phase 1 | Mar 28, 2017 | Bayer |
| NCT02975440 | Phase 1 | Nov 10, 2016 | Bayer |
| NCT02456129 | Phase 1 | Jul 1, 2015 | Bayer |
| NCT02465814 | Phase 2 | Jun 1, 2015 | Bayer |
| NCT02262663 | Phase 1 | Oct 1, 2014 | Bayer |
| NCT02131662 | Phase 2 | May 1, 2014 | Bayer |
| NCT01816815 | Phase 1 | Nov 1, 2011 | Bayer |
Showing 17 of 17 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bayer | For profit | 17 | 17 | 3 | 2011 |
1 organizations
Page 1 / 1